Shwetha Mudalegundi

Shwetha Mudalegundi

Auto-generated profile, based on publicly available information

Shwetha Mudalegundi

Intermountain Ocular Research Center, Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2024 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
NHN.M. Haney
N.M. Haney
TSTamir Sholklapper
Tamir Sholklapper
CCC. Crigger
C. Crigger
AGA. Griggs-Demmin
A. Griggs-Demmin
SMS. Mudalegundi
S. Mudalegundi
CWC.Q. Wu
C.Q. Wu

7 July 2022 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
NHNora M Haney
Nora M Haney
CCChad B Crigger
Chad B Crigger
TSTamir Sholklapper
Tamir Sholklapper
SMShwetha Mudalegundi
Shwetha Mudalegundi
AGAngelica Griggs-Demmin
Angelica Griggs-Demmin
JGJohn P Gearhart
John P Gearhart

16 May 2024 in Journal of Surgical Education
Verified
Journal Article
Closed access
SMShwetha Mudalegundi
Shwetha Mudalegundi
MCMarisa Clifton
Marisa Clifton
SLScott Lifchez
Scott Lifchez
DLDawn LaPorte
Dawn LaPorte
SRSaras Ramanathan
Saras Ramanathan
FWFasika Woreta
Fasika Woreta

21 September 2023 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
SMShwetha Mudalegundi
Shwetha Mudalegundi
PHPeng Huang
Peng Huang
AHAmanda D. Henderson
Amanda D. Henderson
ACAndrew R. Carey
Andrew R. Carey
Background: Thyroid eye disease (TED) is a condition caused by inflammatory damage to the periocular tissue that often leads to double vision. Teprotumumab is an insulin-like growth factor 1 receptor antibody that was FDA approved for the management of TED in 2020, although much is yet to be elucidated regarding its effects on diplopia outcomes among patients with TED. Diplopia is a significant and life-altering effect of TED. Previous studies have reported the effect of teprotumumab on double vision subjectively using the Gorman diplopia score. However, there is a gap in the literature addressing the effect of teprotumumab treatment on objective ocular alignment measures. The purpose of our study was to address this gap. Methods: We performed a retrospective review of patients who were diagnosed with TED, presented with diplopia, and treated with teprotumumab in a single-center academic ophthalmology practice. The primary outcome was change in ocular alignment in primary gaze position at 6 months (completion of teprotumumab treatment). Secondary outcomes included change in ocular alignment in other gaze positions, proptosis, eyelid position, and clinical activity score (CAS) at 6 months compared with baseline. To determine what factors may predict ocular alignment response to teprotumumab, we analyzed baseline characteristics among 3 groups, divided based on whether ocular alignment was worsened, stable, or improved at 6 months. Results: Seventeen patients met inclusion criteria, 3 (18%) worsened, 10 (59%) were stable, and 4 (24%) improved. CAS ( P = 0.02) was significantly different among the groups and was higher in those who worsened and those who improved compared with those who remained stable. Right gaze horizontal prism deviation ( P = 0.01) and left gaze horizontal prism deviation ( P = 0.03) were significantly different among the groups, with a greater degree of left gaze horizontal prism deviation in the worse group than the stable group ( P = 0.04). Conclusions: Our study demonstrated that most patients remained stable after teprotumumab treatment regarding ocular alignment in primary gaze and the number of patients who improved was slightly higher than the number of patients who worsened after teprotumumab treatment. There are some baseline measures, such as CAS and right and left gaze horizontal prism deviation that can help better predict how a patient will respond to teprotumumab treatment. Our results can better inform physicians of how to counsel patients with TED when considering teprotumumab therapy.

21 January 2025 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
MYMelissa Yao
Melissa Yao
SMShwetha Bs Mudalegundi
Shwetha Bs Mudalegundi
KEKevin Eid
Kevin Eid
NBNour Bundogji
Nour Bundogji
NKNeil Kelkar
Neil Kelkar
NMNick Mamalis
Nick Mamalis
Purpose: To identify trends in the reporting of toxic anterior segment syndrome (TASS) to the American Society of Cataract and Refractive Surgery (ASCRS) TASS Force from 2012-2022. Setting: John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA. Design: Cross-sectional study. Methods: TASS questionnaires on instrument cleaning and sterilization, and extraocular and intraocular products used during cataract surgery were available on the American Society of Cataract and Refractive Surgery website. A retrospective analysis of questionnaires submitted by surgical centers reporting cases of TASS was performed between January 1, 2012, and December 31, 2022, to identify commonly held practices that could cause TASS. Results: Data from 77 questionnaires were analyzed. The reporting centers performed 56,319 cataract surgeries and reported 539 cases of TASS from January 1, 2012, to December 31, 2022. Common practices associated with the TASS outbreaks in the surveys included re-use of single-use cannulas, phacoemulsification, and irrigation/aspiration tips (69%), use of enzymatic cleaners (40%), inadequate flushing of phacoemulsification and irrigation/aspiration handpieces (27%), reuse of phacoemulsification tubing (22%), use of preservative-containing intracameral anesthetic (18%), and addition of antibiotics to balanced salt solution (17%). Conclusions: The surveys identified commonly held practices associated with TASS while showcasing trends over the past 10 years. Understanding these findings and the safe alternatives will allow surgical center personnel to change their practices as needed to prevent this complication.

4 November 2022 in Ophthalmology Science
Verified
Journal Article
Open access
SMShwetha Mudalegundi
Shwetha Mudalegundi
RRRobin D. Ross
Robin D. Ross
JLJemma Larbelee
Jemma Larbelee
FAFred Amegashie
Fred Amegashie
RDRobert F. Dolo
Robert F. Dolo
AEAllen O. Eghrari
Allen O. Eghrari
Survivors of Ebola virus disease (EVD) experience decreased intraocular pressure (IOP) relative to unaffected close contacts during the first year of convalescence. Whether this effect persists over time and its relationship to intraocular pathology are unclear. We sought to determine whether IOP remained lower in survivors of EVD over 4 years of follow-up and to identify associated risk factors. Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) III is a 5-year, longitudinal cohort study of survivors of EVD and their close contacts and is a collaboration between the Liberian Ministry of Health and the United States National Institutes of Health. Participants who enrolled in PREVAIL III at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 who underwent comprehensive ophthalmic evaluation annually for 5 consecutive visits. Intraocular pressure was measured at each visit by a handheld rebound tonometer using sterile tips. Comparisons are made between antibody-positive survivors and antibody-negative close contacts. Intraocular pressure, measured in mmHg, at each study visit. Of 565 antibody-positive survivors and 644 antibody-negative close contacts enrolled in the study at baseline, the majority of participants returned annually, with 383 (67.8%) and 407 (63.2%) participants, respectively, presenting for the final study visit at a median of 60 months after symptom onset. A sustained, relative decrease in IOP was observed in survivors relative to close contacts, with mean difference of −0.72 mmHg (95% confidence interval [CI] −1.18 to −0.27) at the final study visit. This difference remained constant throughout the study period (P = 0.4 for interaction over time). Among survivors, physical examination findings of vitreous cell and OCT findings of vitreous opacities both demonstrated a significant association with decreased IOP at baseline (P < 0.05 for both). After adjusting for such factors, the difference throughout the follow-up (−0.93 mmHg, 95% CI, −1.23 to −0.63) remained significant. Survivors of EVD experienced a sustained decrease in IOP relative to close contacts over a 5-year period after EVD. The results highlight the importance of considering long-term sequelae of emerging infectious diseases within a population. Proprietary or commercial disclosure may be found after the references.